Vir Biotechnology, Inc. VIR
Vir Biotechnology, Inc. (Nasdaq: VIR) is an infectious disease drug developer. Its lead program, tobevibart + elebsiran (ECLIPSE program), is in Phase 3 for chronic hepatitis delta (CHD). Its next catalyst on record is VIR-5818: Updated Phase 1 dose-escalation data (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VIR-5818 — Updated Phase 1 dose-escalation data (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| tobevibart + elebsiran (ECLIPSE 1, 2, 3) | chronic hepatitis delta | antibody | Phase 3 |
| VIR-5500 (PSMA PRO-XTEN dual-masked TCE; Astellas collaboration) | PSMA-expressing metastatic castration-resistant prostate cancer | antibody | Phase 1 |
| VIR-5818 (HER2 dual-masked TCE) | HER2-expressing solid tumors | antibody | Phase 1 |
| VIR-5525 (EGFR dual-masked TCE) | EGFR-expressing solid tumors | antibody | Phase 1 |
| HIV bnAbs | HIV cure / long-acting treatment | antibody | Pre-clinical |
| Undisclosed masked TCEs | solid tumors | antibody | Pre-clinical |
Recent results and decisions
- Aug 5, 2026completed enrollment ECLIPSE 2 Phase 3 completed enrollment; entire ECLIPSE program now fully enrolled.
The Company completed enrollment in the Phase 3 ECLIPSE 2 trial, and the entire ECLIPSE registrational program is now fully enrolled.
Filing - Feb 23, 2026positive Updated Phase 1 dose-escalation data for VIR-5500 monotherapy showed dose-dependent anti-tumor activity and well-tolerated safety in mCRPC (no numbers in release).
Positive updated Phase 1 data for VIR-5500 monotherapy showed dose-dependent anti-tumor activity and a well-tolerated safety profile to date in patients with mCRPC.
Filing - Jan 12, 2026positive Updated Phase 2 SOLSTICE: HDV RNA target not detected in 88% (21/24) on combination at Week 96 vs 46% (11/24) on tobevibart alone; 77% (24/31) at Week 72; no grade 3+ treatment-related AEs.
achieved undetectable HDV RNA in 88% of chronic hepatitis delta participants evaluable at 96 Weeks of treatment
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 infectious disease companies
- Gilead Sciences, Inc. GILD
- GSK plc GSK
- Moderna, Inc. MRNA
- Vaxcyte, Inc. PCVX
- Novavax Inc NVAX
- Sinovac Biotech Ltd SVA
- CorMedix Inc. CRMD
- Valneva SE VALN
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.